Meta-analysis Evaluating Calcium Channel Blockers and the Risk of Peripheral Arterial Disease in Patients with Hypertension

Peripheral arterial disease (PAD) is associated with significant morbidity and mortality. It affects 8.5 million Americans aged 40 years and above, and 202 million people worldwide.1 Given the significant burden and resource utilization associated with PAD, strategies for preventing the development of PAD could have an enormous impact. Hypertension is an established risk factor for the development of atherosclerotic vascular disease including PAD. Over the past two decades, several randomized controlled trials (RCTs) have examined the efficacy of various antihypertensive agents in reducing mortality and other major adverse cardiovascular events such as myocardial infarction and stroke.
Source: The American Journal of Cardiology - Category: Cardiology Authors: Source Type: research